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After publication of the original article \[[@CR1]\], the authors wished to submit a number of minor corrections affecting Fig. [2](#Fig2){ref-type="fig"}; Tables [3](#Tab3){ref-type="table"} and [4](#Tab4){ref-type="table"}. Revised versions of these items are published in this erratum.Fig. 2Inter-relationships between the two high-level target product profiles (*center*) with the individual target candidate profiles (*left*) for molecules that are part of the product. The uses for each product are summarized on the *right* Table 3TPP-2 chemoprotection profilesParameter to be demonstrated for the combination in clinical evaluationMinimum essentialIdeal single exposure chemoprotectionDrug productFor elimination phases at least one of the two compounds also with TCP-4, co-formulated. The other should be a long-lasting blood schizonticide TCP-1For elimination phases both molecules should have TCP-4 activity, co-formulatedDosing regimenOral, once per week; injectable once per 3 monthsOral once per month; injectable less frequently than once per 3 monthsRate of onset of actionFor asexual blood-stage action---slow onset (\>48 h)Clinical efficacy≥95% protective efficacy and non-inferior to Standard of Care≥98% protective efficacy and non-inferior to Standard of CareTransmission blockingNoYesBioavailability/food effectPredicted or measured \>30% for each molecule/\<threefoldPredicted or measured \>50% for each molecule/no significant food effectDrug--drug interactionsNo unmanageable risk in terms of solid state or PK interactionsNo risks in terms of solid state or PK interactionsSafety and tolerabilityFew and manageable drug-related SAEs in phase III and IVNo drug-related SAEs; minimal drug-related AEs that do not result in study exclusionUse in patients with reduced G6PD activityTesting not required; no enhanced risk in mild--moderate G6PD deficiencyNo enhanced riskPregnancyNot contra-indicated in second or third trimesterNot contra-indicated in second or third trimester, no suggestion of embryo-fetal toxicity in first trimester in preclinical speciesFormulationsCo-formulated tablets or equivalent, with taste-masking for paediatrics if taste is unacceptable to children\
Long-lasting formulations for intramuscular or intradermal use with low injection volumeCo-formulated tablets for adults. Dispersible or equivalent with taste-masking for paediatricsCost of treatment≤\$1.00 for adults, \$0.25 for infants under 2 years\
Similar to vaccine costs for an injectableIdemShelf life of formulated product (ICH guidelines for Zones III/IV; combination only)≥2 years≥5 yearsSusceptibility to loss of efficacy due to acquired resistanceVery low; no cross resistance with partnerVery low; no cross resistance and orthogonal mechanism from those used in treatment Table 4TCP-1 profiles, molecules that clear asexual parasitaemiaTCP-1 criteria at human proof of conceptMinimum essentialIdealDosing regimen; adult/paediatric doseOral, single dose (predicted) \<1000 mg/\<250 mg; oral, three doses \<400 mg/\<100 mg for areas of multidrug resistanceOral, single dose (predicted); \<100 mg/25 mgRate of onset of action and clinical parasite reduction ratio from single doseRapid clearance of parasites at least as fast as mefloquine (≤72 h from the highest burdens) and projected \>10^6^-fold reduction in parasitesImmediate and rapid clearance of parasites at least as fast as artesunate; \>projected 10^12^-fold reduction in parasitesSusceptibility to loss of efficacy due to acquired resistanceNo fit, transmissible drug-resistant parasites identified in CHMI challenge model; identification of combination partner with no cross resistanceVery low (similar to chloroquine); no cross-resistance with asexual blood-stage combination partner. Resistance markers investigatedRelative clinical efficacy from patients in areas known to be resistant to current first line medicationsClinical efficacy against all known resistance (3-day dosing)Clinical efficacy against all known resistance (single dose)Drug--drug interactionsNo unsurmountable risks with potential anti-malarial partnersNo interactions with other anti-malarial, anti-retroviral or TB medicinesSafetyTherapeutic ratio \>tenfold between therapeutic exposure and NOAEL (no adverse effects level) in preclinical studies, and easily 'monitorable' adverse event or biomarker for human studiesTherapeutic ratio \>50-fold between therapeutic exposure and NOAEL in preclinical studies and easily 'monitorable' adverse event or biomarker for human studiesG6PD (glucose-6-phosphate dehydrogenase) deficiency statusMeasured---no enhanced haemolysis risk from testing in SCID mice engrafted with human blood from volunteers with reduced G6PD activity; clinical confirmationMeasured---no enhanced haemolysis risk in subjects with reduced G6PD activity, with clinical confirmationFormulationSimple and inexpensive to produce, not requiring proprietary methodology or kits; can readily be produced in endemic countriesSimple and inexpensive to produce, not requiring proprietary methodology or kits; can readily be produced in endemic countriesCost of active ingredient in final medicineSimilar to current medication: ≤\$0.5 for adults, \$0.1 for infants under 2 yearsSimilar to older medications: \<\$0.25 for adults, \$0.05 for infants under 2 yearsEstimated stability of final product under Zone IVb conditions (30 °C 75% humidity), in final packaging≥24 months≥3--5 years

The online version of the original article can be found under doi:10.1186/s12936-016-1675-x.
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